IL294071A - Methods of treating conditions related to the s1p1 receptor - Google Patents

Methods of treating conditions related to the s1p1 receptor

Info

Publication number
IL294071A
IL294071A IL294071A IL29407122A IL294071A IL 294071 A IL294071 A IL 294071A IL 294071 A IL294071 A IL 294071A IL 29407122 A IL29407122 A IL 29407122A IL 294071 A IL294071 A IL 294071A
Authority
IL
Israel
Prior art keywords
compound
individual
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Application number
IL294071A
Other languages
English (en)
Hebrew (he)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IL294071A publication Critical patent/IL294071A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL294071A 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor IL294071A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062957535P 2020-01-06 2020-01-06
PCT/US2021/012367 WO2021142030A1 (en) 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
IL294071A true IL294071A (en) 2022-08-01

Family

ID=76788331

Family Applications (1)

Application Number Title Priority Date Filing Date
IL294071A IL294071A (en) 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor

Country Status (12)

Country Link
US (1) US20230338336A1 (enExample)
EP (1) EP4087562A4 (enExample)
JP (1) JP2023509698A (enExample)
KR (1) KR20220124209A (enExample)
CN (1) CN115066242A (enExample)
AU (1) AU2021205465A1 (enExample)
BR (1) BR112022012846A2 (enExample)
CA (1) CA3166828A1 (enExample)
IL (1) IL294071A (enExample)
MX (1) MX2022008342A (enExample)
TW (1) TW202135804A (enExample)
WO (1) WO2021142030A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240065283A (ko) * 2021-09-23 2024-05-14 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법
WO2023135506A1 (en) * 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
KR102541577B1 (ko) 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469863A2 (en) * 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
PL2498610T5 (pl) * 2009-11-13 2024-11-04 Receptos Llc Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
HUE036391T2 (hu) * 2009-11-13 2018-07-30 Celgene Int Ii Sarl Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások
CN105130922A (zh) * 2009-11-13 2015-12-09 瑞塞普托斯公司 选择性的杂环1-磷酸鞘氨醇受体调节剂
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法

Also Published As

Publication number Publication date
CN115066242A (zh) 2022-09-16
MX2022008342A (es) 2022-08-04
TW202135804A (zh) 2021-10-01
KR20220124209A (ko) 2022-09-13
EP4087562A4 (en) 2024-01-10
JP2023509698A (ja) 2023-03-09
CA3166828A1 (en) 2021-07-15
US20230338336A1 (en) 2023-10-26
WO2021142030A1 (en) 2021-07-15
BR112022012846A2 (pt) 2022-09-06
EP4087562A1 (en) 2022-11-16
AU2021205465A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
US20230338336A1 (en) Methods of treating conditions related to the s1p1 receptor
EP3582814B1 (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
WO2007119214A2 (en) Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
AU2022337087A1 (en) Lou064 for treating multiple sclerosis
US20200383956A1 (en) METHODS OF TREATING KERATIN HYPERPROLIFERATION DISORDERS USING mTOR INHIBITORS
AU2024204716A1 (en) Treatment of alopecia areata
WO2019186171A1 (en) Treatment of sarcopenic diseases
CN120267673A (zh) 用于治疗癌症的剂量方案
CN113423402A (zh) 癌症治疗
JP2023502355A (ja) S1p1受容体に関連する状態を処置する方法
Yue et al. Treatment of refractory progressive vitiligo with oral upadacitinib and narrow‐band ultraviolet‐B: A case series.
Wernicke et al. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP)
HK40080125A (en) Methods of treating conditions related to the s1p1 receptor
CN121712505A (zh) 使用因子b抑制剂的方法
TW202114656A (zh) 治療與s1p1 受體相關之病況的方法
KR102585038B1 (ko) 렙틴 수용체 길항제 펩타이드를 유효성분으로 함유하는 유방암 치료용 약학적 조성물
HK40085111A (en) Dosage regimen for the treatment of cancer
Tekgul et al. Lymphocyte subsets in Bell's palsy: immune pathogenesis and outcome prediction
JP2024537906A (ja) 粘膜炎を処置するための組成物及び方法
JP5678566B2 (ja) 乾癬予防治療剤
US20060084591A1 (en) Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases
EA052711B1 (ru) Лечение рака
EP4673123A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
HK40019900A (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
HK40019900B (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations